Hansa Biopharma AB
Clinical trials sponsored by Hansa Biopharma AB, explained in plain language.
A biopharmaceutical company developing immunomodulatory therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug could unlock kidney transplants for sensitized kids Results expected Feb 2027 (estimated)
-
5-year follow-up checks if imlifidase helps kidney transplants last longer
Disease control OngoingThis study follows 150 people who received imlifidase before a kidney transplant to see how long their new kidney works. Researchers will check for graft failure (return to dialysis, re-transplant, or kidney removal) over 5 years. A separate group of similar patients not receivin…
Phase 3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug may help Hard-to-Transplant kidney patients stay off dialysis longer
Disease control OngoingThis study follows 64 highly sensitized kidney transplant patients who previously received either imlifidase or standard care in an earlier trial. Researchers will track how many patients are alive and free of dialysis at 3 and 5 years, as well as graft survival. The goal is to s…
Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC